



Resonance Health Ltd
ASX / Media Release

17 June 2014

Close of Entitlement Offer
Notice of Shortfall

Resonance Health Ltd (ASX: RHT) advises that the Non-renounceable Entitlement Offer announced on 9 April 2014 closed for acceptances on 13 June 2014. This followed completion of the successful institutional placement at the same price per share which raised \$0.5 million.

In accordance with Appendix 7A of the ASX Listing Rules, the Company advises the following:

- The Company received acceptances for a total of 15,550,419 new shares raising \$0.777 million;
- As such, there is a shortfall under the Entitlement Offer of 77,197,422 shares.

The allotment of new shares under the Entitlement Offer has taken place on 16th June 2014 and ASX trading of the new shares is expected to commence on 20th June 2014.

The Directors have reserved the right to place the shortfall no later than three months after the closing date of the offer in accordance with the ASX Listing Rules. Azure Capital Limited act as Lead Manager in relation to the Placement and Entitlement Offer and will be assisting with the placement of the shortfall.

The directors wish to thank shareholders for their continued support of the Company. As outlined in the Offer Document, the funds will be used to further the development and commercialisation of the Company's MRI based intellectual property and other products.

For further information please contact:

Resonance Health

Adrian Bowers
Company Secretary
T: +61 8 9286 5300
E: adrianb@resonancehealth.com

Liza Dunne
Managing Director
T: +61 8 9286 5300
E: lizad@resonancehealth.com

Resonance Health Ltd (ASX: RHT) (www.resonancehealth.com) is a medical device company providing imaging core laboratory services for the quantitative analysis of MR medical images, with a subspecialty in the liver. Resonance Health's patented FerriScan technology provides a safe and accurate alternative for measuring liver iron concentration. HepaFat-Scan is FDA cleared for the measurement of liver fat and research continues into the development of new technology for the accurate assessment of liver fibrosis.